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FIGURE 3.  Predicted protein structure of the 
double mutant E746V-L747P. This structural rear-
rangement allows ATP (orange and blue chemi-
cal structure) binding, even in the presence of 
gefitinib (purple chemical structure), in a favor-
able position for hydrolysis. Visual analysis of the 
protein structures based on native EGFR alone, in 
complex either with tyrosine kinase inhibitor or 
ATP analogue, mutated EGFR with gefitinib from 
Protein Data Bank (http://www.rcsb.org/pdb/
home/home.do. Accessed February 10, 2015; 
PDB: 4WRG, 4WKQ, 4HJO, 4G5J, 4I23, 3VJO, 
4I22), was carried over using the program COOT 
and figure was drawn using the program Chimera.
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To the Editor:
The recent report on “MicroRNA 
Assays to Distinguish Squamous Cell 
Carcinoma from Adenocarcinoma in 
Lung Cancer Biopsies” is very interest-
ing.1 Patnaik et al.1 noted that “histotypic 
microRNA assays can aid the subtyping 
of non-small-cell lung cancer biopsies as 
Istituto Nazionale per la Ricerca sul 
Cancro
Genova, Italy 
Francesco Boccardo, MD
Dipartimento di Medicina Interna e 
Specialità Mediche (DIMI)
IRCCS AOU San Martino-IST
Istituto Nazionale per la Ricerca sul 
Cancro
Genova, Italy
UOC Clinica di Oncologia Medica, 
IRCCS AOU San Martino-IST
Istituto Nazionale per la Ricerca sul 
Cancro 
Genova, Italy 
Francesco Grossi, MD
Lung Cancer Unit
IRCCS AOU San Martino-IST
Istituto Nazionale per la Ricerca sul 
Cancro
Genova, Italy 
ACkNOwlEDGEmENtS
The present study was supported 
by "Fondazione Carige" (2013.0277-
12) and the Italian Ministry of Health 
(GR 2011-12; 02350922; SC). We thank 
Drs. Cristina Bruzzo and Zita Cavalieri 
for technical support. We are grateful 
to the tissue bank Centro di Risorse 
Biologiche-IST (CRB-IST).
REFERENCES
 1. van der Wekken AJ, Stigt JA, A’t Hart N. A 
novel EGFR mutation in exon 19 showed 
stable disease after TKI treatment. J Thorac 
Oncol 2012;7:e8.
 2. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, 
Yang PC. Effectiveness of tyrosine kinase 
inhibitors on “uncommon” epidermal growth 
factor receptor mutations of unknown clini-
cal significance in non-small cell lung cancer. 
Clin Cancer Res 2011;17:3812–3821.
 3. Niho S, Kubota K, Goto K, et al. First-line sin-
gle agent treatment with gefitinib in patients 
with advanced non-small-cell lung cancer: a 
phase II study. J Clin Oncol 2006;24:64–69.
 4. Gajiwala KS, Feng J, Ferre R, et al. Insights 
into the aberrant activity of mutant EGFR 
kinase domain and drug recognition. Structure 
2013;21:209–219.
 5. He M, Capelletti M, Nafa K, et al. EGFR 
exon 19 insertions: a new family of sensi-
tizing EGFR mutations in lung adenocarci-
noma. Clin Cancer Res 2012;18:1790–1797.
Copyright © 2015 by the International Association for the Study of Lung Cancer
e53Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015 Letters to the Editor
Reply to “MiR-
205 and miR-375 
microRNA Assays to 
Distinguish Squamous 
Cell Carcinoma From 
Adenocarcinoma in 
Lung Cancer Biopsies”
adenocarcinoma (AC) or squamous cell 
carcinoma (SCC) by standard histopath-
ologic methods.” In fact, adding a new 
diagnostic tool to the classical diagnostic 
tool might improve the diagnostic ability. 
Focusing on the use of microRNAassays, 
there are still left concern and questions 
on the cost effectiveness, availability, and 
complexity of the tests. These points have 
to be further discussed. Focusing on MiR-
205 MicroRNA, its diagnostic value for 
differentiating between AC and SCC is 
still controversial. Some previous reports 
showed limitation of its ability to diag-
nose SCC.2 Also, the MiR-205 can also 
increase in the case with severe inflam-
mation and benign tumor.3 The possibility 
of false-positive because of noncancerous 
lesion has to be further studied.
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In Response:
We thank Dr. Wiwanitkit for 
his comments on our study.1 The 
microRNA-based assay described in it 
requires the quantification of only four 
RNAs (miR-21, miR-205, and miR-375, 
and RNU6B). As already noted by us in 
the publication, this can be conveniently 
done in any laboratory with a quantita-
tive polymerase chain reaction machine, 
with time and material costs similar to 
those for immunohistochemistry-based 
diagnosis of non–small-cell lung can-
cer histology. However, the suitability 
of the assay for biospecimens with less 
than 90% tumor content has not been 
assessed by us. In our study, microdis-
section of tumor-containing regions of 
biopsied material was performed for 
76% of biopsies to have ≥90% tumor 
content in the specimens that were used 
for RNA extraction for the microRNA-
based assay.
The studies on the association 
of miR-205 with severe inflammation 
and benign tumor and the lack of a dif-
ferential expression of this microRNA 
between normal and tumor tissues, 
which Dr. Wiwanitkit refers to, con-
cern oral cancer and not cancer of the 
lung. In case of the latter, a significantly 
higher expression of miR-205 in lung 
squamous cell carcinoma tissue com-
pared with normal lung, or lung tissue 
with adenocarcinoma or benign dis-
eases has been noted by many2–5 and in 
Figure 1 of our article.1
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In Response:
We would like to thank Dr. Tapias 
and Dr. Lanuti for their comments on 
our recent article reporting on a mul-
ticenter cohort of 68 patients with 
solitary fibrous tumors of the pleura 
(SFTP), who were analyzed for the 
complete course of the disease in a 
routine practice setting.1 We acknowl-
edge that our recurrence rate of 30% 
Reply to “Better 
Prognostic Models 
May Result in 
Improved Patient 
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